Synthetic Neurovascular Tissue (SNT) is the universal biocompatible interface layer that enables the integration of cybernetic implants with organic tissue. Developed by Cortex Dynamics in 2091 and refined through seven generations of improvement, SNT is the single most important medical technology of the 22nd century. Without it, cyberware is a foreign object bolted to flesh. With it, cyberware becomes an extension of the body.

SNT is a living material. It is not a coating, a sealant, or an adhesive. It is a synthetic organism — a sheet of engineered cells that performs three simultaneous functions:

1. VASCULAR INTEGRATION: SNT grows capillary networks that connect the implant's microfluidic channels to the body's circulatory system. This allows the implant to receive nutrients, regulate temperature, and exchange metabolic waste through the same blood supply as organic tissue.

2. NEURAL BRIDGING: SNT neurons form synaptic connections between the implant's electrode array and the body's peripheral or central nervous system. This provides bidirectional signal transmission — the brain can control the implant, and the implant can feed sensory data back to the brain.

3. STRUCTURAL BONDING: SNT generates a collagen-rich matrix that physically anchors the implant to bone, muscle, or connective tissue. This prevents migration, reduces inflammation, and distributes mechanical stress across a broad interface area rather than concentrating it at attachment points.

The integration process takes 2-6 weeks depending on implant complexity and patient physiology. During this period, the SNT layer is metabolically active — growing, adapting, and establishing connections. Patients describe a tingling sensation at the implant site that gradually transitions to normal sensation as neural bridging completes.

SNT is manufactured exclusively by three licensed producers: Cortex Dynamics (original developer), Tessera BioSystems (Tessera Corponation subsidiary), and Liang-Petrova Medical Division. The manufacturing process requires controlled microgravity conditions, which is why all SNT is produced at the Ascension Tether's counterweight station. This gives the three producers — and by extension, Meridian Orbital Dynamics — an effective monopoly on the material that makes every cybernetic implant on Earth functional.

Current-generation SNT (Gen 7, designated SNT-7) achieves 99.4% integration success rates with rejection events occurring in fewer than 0.6% of standard implantation procedures. Rejection, when it occurs, presents as localized necrosis at the bonding site and requires immediate surgical removal of the implant.